Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Addressing bone marrow lesions that compromise osteochondral tissue repair

Award Number: R41AR083778
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/18/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Addressing bone marrow lesions that compromise osteochondral tissue repair - ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient population, Cytex is developing implants pairing a patented 3D weaving technology with additive manufacturing to facilitate cartilage and bone regeneration. The implant is designed to support joint loading immediately upon implantation and to allow integration and development of osteochondral tissue. Other cartilage repair treatments have promising clinical results, but can lead to the formation of fibrous tissue, apoptosis, and further cartilage degeneration. Further, in the knee, subchondral bone marrow cysts, bone marrow lesions (BML), and edema commonly undermine cartilage repair, with iatrogenic damage to the subchondral bone resulting in considerable and complex issues for long-term clinical outcomes from the repair procedure. Cytex implants have demonstrated the capability of repairing osteochondral lesions and restoring pain-free joint function for extended durations in large animal models of hip OA. Conversely, in the knee joint, we have routinely observed significant BMLs that result in graft failure. The ingress of synovial fluid with pro-inflammatory cytokines into the bone is a proposed mechanism for BML formation. Based on this mechanism, we established an animal model of BMLs alongside imaging optimization for detection of BMLs. The objective of the current proposal is to develop and test an acellular implant specific to cartilage repair in the knee and other joints where BMLs are common. We hypothesize that reducing implant permeability at the time of implantation will prevent the ingress of synovial fluid into the bone cavity and prevent BMLs, allowing the implant to restore joint congruity. Building on our pilot work, we will incorporate crosslinked hyaluronic acid (HA) gels into our 3D woven textile. These HA gels have shown relative impermeability and limited inflammatory response in vivo. We will select an optimized gel based on sustained relative impermeability while allowing for significant in vitro gel degradation over 8 weeks. In an in vivo study, the resulting HA-gel implants will be compared against an unmodified acellular implant (permeable control) and microfracture (“standard of care” control) with success criteria based on BML severity, OA severity, and implant functional characteristics (mechanical properties and cartilage repair). Forming a temporary biological barrier in the textile component of our implant should prevent the formation of a BML while also ensuring the ability of the Cytex implant to repair and regenerate the damaged cartilage in the knee.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2023	CYTEX THERAPEUTICS INC	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	2/26/2026	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	CYTEX THERAPEUTICS, INC.	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	10/17/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $282,265 )
2023	2023	CYTEX THERAPEUTICS, INC.	2609 N DUKE ST STE 303A	DURHAM	NC	27704	DURHAM	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/18/2023	NEW	$282,265
														Subtotal = $282,265

Grand Total All Awards = $282,265

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Addressing bone marrow lesions that compromise osteochondral tissue repair

Award Number: R41AR083778

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/18/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer